# China Pharma Holdings, Inc.: financial statements, quarterly

CPHI · NYSE · CIK 1106644 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cphi.md) · [Financials](/companies/cphi/financials.md) · [Filings](/companies/cphi/filings.md) · [Insiders](/companies/cphi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cphi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [1,803](/filings/0001213900-24-097461.md) | [2,150 d](/filings/0001213900-25-026280.md) | [1,370](/filings/0001213900-25-043334.md) | [925](/filings/0001213900-25-076642.md) | [1,100](/filings/0001213900-25-109203.md) | [1,134 d](/filings/0001213900-26-038521.md) | [1,136](/filings/0001213900-26-057705.md) | [1,026](/filings/0001213900-26-090173.md) | [756](/filings/0001213900-25-109203.md) | [1,226 d](/filings/0001213900-26-038521.md) | [984](/filings/0001213900-26-057705.md) | [948](/filings/0001213900-26-090173.md) |
| Cost of revenue | $k | [2,037](/filings/0001213900-24-097461.md) | [2,229 d](/filings/0001213900-25-026280.md) | [1,660](/filings/0001213900-25-043334.md) | [1,940](/filings/0001213900-25-076642.md) | [1,620](/filings/0001213900-25-109203.md) | [1,295 d](/filings/0001213900-26-038521.md) | [1,272](/filings/0001213900-26-057705.md) | [1,113](/filings/0001213900-26-090173.md) | [816](/filings/0001213900-25-109203.md) | [1,075 d](/filings/0001213900-26-038521.md) | [698](/filings/0001213900-26-057705.md) | [865](/filings/0001213900-26-090173.md) |
| Gross profit | $k | [(233)](/filings/0001213900-24-097461.md) | [(79.2) d](/filings/0001213900-25-026280.md) | [(290)](/filings/0001213900-25-043334.md) | [(1,015)](/filings/0001213900-25-076642.md) | [(520)](/filings/0001213900-25-109203.md) | [(161) d](/filings/0001213900-26-038521.md) | [(136)](/filings/0001213900-26-057705.md) | [(87.0)](/filings/0001213900-26-090173.md) | [(59.7)](/filings/0001213900-25-109203.md) | [151 d](/filings/0001213900-26-038521.md) | [285](/filings/0001213900-26-057705.md) | [83.6](/filings/0001213900-26-090173.md) |
| Research and development | $k | [45.8](/filings/0001213900-24-097461.md) | [148 d](/filings/0001213900-25-026280.md) | [31.5](/filings/0001213900-25-043334.md) | [164](/filings/0001213900-25-076642.md) | [87.6](/filings/0001213900-25-109203.md) | [0.5 d](/filings/0001213900-26-038521.md) | [29.6](/filings/0001213900-26-057705.md) | [21.0](/filings/0001213900-26-090173.md) | [40.3](/filings/0001213900-25-109203.md) | [190 d](/filings/0001213900-26-038521.md) | [83.8](/filings/0001213900-26-057705.md) | [19.1](/filings/0001213900-26-090173.md) |
| Operating income | $k | [(714)](/filings/0001213900-24-097461.md) | [(1,184) d](/filings/0001213900-25-026280.md) | [(916)](/filings/0001213900-25-043334.md) | [(1,392)](/filings/0001213900-25-076642.md) | [(1,085)](/filings/0001213900-25-109203.md) | [(1,196) d](/filings/0001213900-26-038521.md) | [(759)](/filings/0001213900-26-057705.md) | [(652)](/filings/0001213900-26-090173.md) | [(628)](/filings/0001213900-25-109203.md) | [(1,200) d](/filings/0001213900-26-038521.md) | [(1,117)](/filings/0001213900-26-057705.md) | [(1,432)](/filings/0001213900-26-090173.md) |
| Interest expense | $k | [6.9](/filings/0001213900-24-097461.md) | [9.7 d](/filings/0001213900-25-026280.md) | [6.9](/filings/0001213900-25-043334.md) | [6.9](/filings/0001213900-25-076642.md) | [6.8](/filings/0001213900-25-109203.md) | [6.8 d](/filings/0001213900-26-038521.md) | [6.8](/filings/0001213900-26-057705.md) | [6.8](/filings/0001213900-26-090173.md) | [6.8](/filings/0001213900-25-109203.md) | [6.9 d](/filings/0001213900-26-038521.md) | [9.1](/filings/0001213900-26-057705.md) | [9.3](/filings/0001213900-26-090173.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(778)](/filings/0001213900-24-097461.md) | [(1,232) d](/filings/0001213900-25-026280.md) | [(956)](/filings/0001213900-25-109203.md) | [(1,438)](/filings/0001213900-25-109203.md) | [(1,118)](/filings/0001213900-25-109203.md) | [(1,224) d](/filings/0001213900-26-038521.md) | [(786)](/filings/0001213900-26-090173.md) | [(528)](/filings/0001213900-26-090173.md) | [(651)](/filings/0001213900-25-109203.md) | [(1,222) d](/filings/0001213900-26-038521.md) | [(1,143)](/filings/0001213900-26-090173.md) | [(1,458)](/filings/0001213900-26-090173.md) |
| Diluted EPS | $ per share | [(0.29)](/filings/0001213900-24-097461.md) | not reported | [(0.72)](/filings/0001213900-25-043334.md) | [(0.89)](/filings/0001213900-25-076642.md) | [(0.65)](/filings/0001213900-25-109203.md) | not reported | [(0.24)](/filings/0001213900-26-057705.md) | [(0.16)](/filings/0001213900-26-090173.md) | [(0.17)](/filings/0001213900-25-109203.md) | not reported | [(0.04)](/filings/0001213900-26-057705.md) | [(0.04)](/filings/0001213900-26-090173.md) |
| Basic EPS | $ per share | [(0.29)](/filings/0001213900-24-097461.md) | not reported | [(0.72)](/filings/0001213900-25-043334.md) | [(0.89)](/filings/0001213900-25-076642.md) | [(0.65)](/filings/0001213900-25-109203.md) | not reported | [(0.24)](/filings/0001213900-26-057705.md) | [(0.16)](/filings/0001213900-26-090173.md) | [(0.17)](/filings/0001213900-25-109203.md) | not reported | [(0.04)](/filings/0001213900-26-057705.md) | [(0.04)](/filings/0001213900-26-090173.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.4](/filings/0001213900-23-086100.md) | [1.4](/filings/0001213900-24-028731.md) | not reported | not reported | [0.7](/filings/0001213900-24-097461.md) | [0.6](/filings/0001213900-26-038521.md) | [0.4](/filings/0001213900-25-043334.md) | [0.6](/filings/0001213900-25-076642.md) | [0.3](/filings/0001213900-25-109203.md) | [0.3](/filings/0001213900-26-090173.md) | [0.2](/filings/0001213900-26-057705.md) | [0.3](/filings/0001213900-26-090173.md) |
| Current assets | $m | [5.8](/filings/0001213900-23-086100.md) | [6.0](/filings/0001213900-25-026280.md) | not reported | [4.0](/filings/0001213900-24-068984.md) | [3.7](/filings/0001213900-24-097461.md) | [3.3](/filings/0001213900-26-038521.md) | [2.9](/filings/0001213900-25-043334.md) | [2.7](/filings/0001213900-25-076642.md) | [2.3](/filings/0001213900-25-109203.md) | [2.3](/filings/0001213900-26-090173.md) | [2.0](/filings/0001213900-26-057705.md) | [2.0](/filings/0001213900-26-090173.md) |
| Total assets | $m | [15.4](/filings/0001213900-23-086100.md) | [16.5](/filings/0001213900-25-026280.md) | not reported | [14.3](/filings/0001213900-24-068984.md) | [13.5](/filings/0001213900-24-097461.md) | [14.9](/filings/0001213900-26-038521.md) | [14.2](/filings/0001213900-25-043334.md) | [13.8](/filings/0001213900-25-076642.md) | [15.8](/filings/0001213900-25-109203.md) | [31.0](/filings/0001213900-26-090173.md) | [45.1](/filings/0001213900-26-057705.md) | [44.7](/filings/0001213900-26-090173.md) |
| Current liabilities | $m | [7.1](/filings/0001213900-23-086100.md) | [6.8](/filings/0001213900-25-026280.md) | not reported | [4.7](/filings/0001213900-24-068984.md) | [4.8](/filings/0001213900-24-097461.md) | [5.0](/filings/0001213900-26-038521.md) | [5.1](/filings/0001213900-25-043334.md) | [5.3](/filings/0001213900-25-076642.md) | [6.6](/filings/0001213900-25-109203.md) | [7.4](/filings/0001213900-26-090173.md) | [7.3](/filings/0001213900-26-057705.md) | [7.7](/filings/0001213900-26-090173.md) |
| Total liabilities | $m | [9.2](/filings/0001213900-23-086100.md) | [9.0](/filings/0001213900-25-026280.md) | not reported | [6.9](/filings/0001213900-24-068984.md) | [6.9](/filings/0001213900-24-097461.md) | [7.1](/filings/0001213900-26-038521.md) | [7.2](/filings/0001213900-25-043334.md) | [7.3](/filings/0001213900-25-076642.md) | [7.5](/filings/0001213900-25-109203.md) | [8.3](/filings/0001213900-26-090173.md) | [8.1](/filings/0001213900-26-057705.md) | [8.5](/filings/0001213900-26-090173.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | [1.1](/filings/0001213900-25-026280.md) | not reported | not reported | not reported | [1.1](/filings/0001213900-26-038521.md) | [1.2](/filings/0001213900-25-043334.md) | [1.4](/filings/0001213900-25-076642.md) | [1.4](/filings/0001213900-25-109203.md) | [1.4](/filings/0001213900-26-090173.md) | [1.5](/filings/0001213900-26-057705.md) | [1.6](/filings/0001213900-26-090173.md) |
| Shareholders' equity | $m | [6.1](/filings/0001213900-24-097461.md) | [7.5](/filings/0001213900-26-038521.md) | [8.3](/filings/0001213900-25-109203.md) | [7.4](/filings/0001213900-25-109203.md) | [6.5](/filings/0001213900-25-109203.md) | [7.7](/filings/0001213900-26-090173.md) | [7.0](/filings/0001213900-26-090173.md) | [6.5](/filings/0001213900-26-090173.md) | [8.3](/filings/0001213900-25-109203.md) | [22.7](/filings/0001213900-26-090173.md) | [37.0](/filings/0001213900-26-090173.md) | [36.2](/filings/0001213900-26-090173.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [1,007 d](/filings/0001213900-24-097461.md) | [(22.3) d](/filings/0001213900-25-026280.md) | [(585)](/filings/0001213900-25-043334.md) | [(72.7) d](/filings/0001213900-25-076642.md) | [(47.0) d](/filings/0001213900-25-109203.md) | [299 d](/filings/0001213900-26-038521.md) | [(73.7)](/filings/0001213900-26-057705.md) | [274 d](/filings/0001213900-26-090173.md) | [(204) d](/filings/0001213900-25-109203.md) | [152 d](/filings/0001213900-26-038521.md) | [(55.3)](/filings/0001213900-26-057705.md) | [(32.8) d](/filings/0001213900-26-090173.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | [(9.2) d](/filings/0001213900-25-109203.md) | [19.5 d](/filings/0001213900-26-038521.md) | [58.3](/filings/0001213900-26-057705.md) | [(0.1) d](/filings/0001213900-26-090173.md) | [0.6 d](/filings/0001213900-25-109203.md) | [0.5 d](/filings/0001213900-26-038521.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2013 (2013-03-31) | Q2 FY2013 (2013-06-30) | Q1 FY2015 (2015-03-31) | Q2 FY2015 (2015-06-30) | Q3 FY2015 (2015-09-30) | Q1 FY2016 (2016-03-31) | Q2 FY2016 (2016-06-30) | Q3 FY2016 (2016-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [43.6](/filings/0001010549-13-000329.md) | [43.6](/filings/0001010549-13-000521.md) | [43.6](/filings/0001010549-16-000606.md) | [43.6](/filings/0001010549-16-000678.md) | [43.6](/filings/0001010549-16-000787.md) | [43.6](/filings/0001010549-16-000606.md) | [43.6](/filings/0001010549-16-000678.md) | [43.6](/filings/0001010549-16-000787.md) | [3.3](/filings/0001213900-26-057705.md) | [3.2](/filings/0001213900-26-090173.md) | [25.6](/filings/0001213900-26-057705.md) | [40.5](/filings/0001213900-26-090173.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 43,022,002 at 2026-08-11, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-090173.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.